About Katie
Katie Lynne Strong is a patent agent in our Intellectual Property & Technology Practice and has extensive experience in all aspects of global patent protection, including US and international patent prosecution, patentability and freedom to operate analysis, and due diligence.
Katie’s scientific acumen; notably her expertise in organic chemistry, medicinal chemistry, nucleoside chemistry, drug design, pharmacology, electrophysiology, anti-viral drugs, and ocular and polymeric formulation, is highly valued by a broad spectrum of clients, particularly those in the biotechnology, chemical and pharmaceutical industries.
Credentials
Education
- Emory University, Ph.D., Organic Chemistry, 2015
- University of Mary WashingtonChemistry, Cum Laude, 2010
Admissions
- U.S. Patent and Trademark Office, 2017
Expertise
Services
- Intellectual Property & Technology
Industries
- Life Sciences
Publications
- Strong K.L.; Epplin M.P.; Ogden K.K.; Burger P.B.; Kaiser T.M.; Wilding T.J.; Kusumoto H.; Camp C.R.; Shaulsky G; Bhattacharya S; Perszyk R.E.; Menaldino D.S.; McDaniel M.J.; Zhang J.; Le P.; Banke T.G.; Hansen K.B.; Huettner J.E.; Liotta D.C.; Traynelis S.F.; Distinct GluN1 and GluN2 Structural Determinants for Subunit-Selective Positive Allosteric Modulation of N-Methyl-d-aspartate Receptors. ACS Chem Neurosci. 2021, 12, 79-98.
- Strong, K.L. Epplin, M.P.; Bacsa, J.; Butch, Cj.; Burger, P.B.; Menaldino, D.S.; Traynelis, S. F.; Liotta, D.C. The Structure-Activity Relationship of a Tetrahydroisoquinoline Class of N-Methyl-d-Aspartate Receptor Modulators that Potentiates GluN2B-Containing N-Methyl-d-Aspartate Receptors. Journal of Medicinal Chemistry. 2017, 60, 5556-5585.
- Strong, K.L.; Epplin, M.P.; Jing, Y.; Traynelis, S.F.; Liotta, D.C. Mechanism of action of a GluN2C- and GluN2D-selective NMDA receptor positive allosteric modulator. In Allosterism in Drug Discovery, Dotter, D., Ed.; Royal Society of Chemistry; Cambridge, 2016; pp 281-309.
- Strong K.L.; Jing Y.; Prosser A.R.; Traynelis S.F.; Liotta D.C. NMDA receptor modulators: an updated patent review (2013-2014). Expert Opin Ther Pat. 2014, 24, 1349-66.
- Perszyk, R.E.; DiRaddo, .1.0.; Strong, K.L.; Low, C.; Ogden, K.K.; Khatri, A.; Vargish, G.A.; Pelkey, K.A.; Tricoire, L.; Liotta, D.C.; Smith, Y.; McBain, C.J.; Traynelis, S.F. GluN2D-containing N-methyl-D-aspartate receptors mediate synaptic transmission in Hippocampal Interneurons and Regulate Interneuron Activity. Mol Pharmacol. 2016, 90, 689-702.
- Santangelo, R.M.; Ogden, K.K.; Strong, K.L.; Khatri, A.; Chepiga, K.M.; Jensen, H.S.; Traynelis, S.F.; Liotta, D.C. Synthesis and Structure Activity Relationship of Tetrahydroisoquinoline-based Potentiators of GIuN2C and GIuN2D Containing N-Methyl-D-Aspartate Receptors. Med. Chem. 2013, 56, 5351-5381.
- Santangelo, R.M.; Acker, T.M.; Zimmerman, SS; Katzman, B.M.; Strong, K.L.; Traynelis, S.F.; Liotta, D.C. Novel NMDA receptor modulators: an update. Expert Opinion on Therapeutic Patents. 2012, 22, 1337-1352.
About our firm
One of the world’s strongest integrated law firms, providing insight at the point where law, business and government meet. We deliver commercially focused business solutions by combining our legal, lobbying and political capabilities and invaluable connections on the ground to a diverse mix of clients, from long-established leading corporations to emerging businesses, startup visionaries and sovereign nations. More than 1,500 lawyers in over 40 offices across four continents provide unrivaled access to expertise.